Combined therapy to prevent complete pelvic exenteration for rhabdomyosarcoma of the vagina or uterus.
Three children with rhabdomyosarcoma (sarcoma botryoides) of the vagina or uterus were managed by modified radical resection combined with pre- and/or postoperative chemotherapy and high-dose irradiation. This plan of therapy contrasts sharply with the conventional approach: i.e., pelvic exenteration consisting of cystectomy, hystovaginectomy, and oophorectomy, with urinary diversion by ureteroileostomy or ureterosigmoidostomy. Two patients had complete regressions of tumor following preoperative chemotherapy and irradiation. The third patient received no preoperative therapy, but was given postoperative radium implantation, irradiation, and chemotherapy. The surgical approach consisted of hystovaginectomy and oophorectomy without urinary diversion. These patients are free of tumor for 32, 44, and 54 months, respectively.  There were no serious toxic reactions to the drugs, nor any significant postoperative urinary tract problems. The results reported here suggest that hystovaginectomy and oophorectomy coordinated with chemotherapy and irradiation is an acceptable alternative to pelvic exenteration in patients with sarcoma botryoides of the vagina or uterus.
D000293:Adolescent; D002648:Child; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D010053:Ovary / Q000601:surgery; D011867:Radioisotope Teletherapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D014594:Uterine Neoplasms / Q000628:therapy*; D014625:Vaginal Neoplasms / Q000628:therapy*; D014750:Vincristine / Q000627:therapeutic use
D003037:Cobalt Radioisotopes; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide